All News
Filter News
Found 2,722 articles
-
AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
8/25/2023
To help protect access to medicines for cancer and rare disease patients, AstraZeneca has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act.
-
Dr. Christian Brander and Dr. Mala Maini Join World-class Scientific Advisory Board of AstriVax
8/22/2023
AstriVax is pleased to announce that Dr. Christian Brander and Dr. Mala Maini have agreed to join the company’s scientific advisory board.
-
The biopharma’s acute myeloid leukemia hopeful is on partial clinical hold, affecting two Phase III AML studies, Gilead announced Monday. The CD47 candidate also spent four months on hold in 2022.
-
The clinical-stage company joins several others in the anti-CD47 space which have dropped studies amid poor results, including Gilead Sciences’ decision late last month to stop a Phase III trial.
-
DermaSensor Study Results For Skin Cancer Detection Device Performance Across Skin Tones Of Over 1,000 Patients
8/10/2023
DermaSensor Inc. presented promising results from a sub-analysis of the DERM-SUCCESS study.
-
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
8/10/2023
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2023, and provided an update on the Company’s portfolio of clinical programs in development.
-
Following a handful of clinical failures and changes to its leadership, FibroGen is trying to chart a more positive path forward by focusing on four strategic areas.
-
Alpha Pro Tech, Ltd. Announces Second Quarter 2023 Financial Results
8/8/2023
Alpha Pro Tech, Ltd., a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, announced financial results for the three and six month periods ended June 30, 2023.
-
Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer
8/7/2023
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Deanna M. Petersen, MBA, as its Chief Business Officer.
-
FibroGen Reports Second Quarter 2023 Financial Results
8/7/2023
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2023 and provided an update on the Company’s recent developments.
-
PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)
8/5/2023
PacBio announced that PacBio's Compensation Committee of the Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock and restricted stock units covering 184,700 shares of PacBio common stock to fourteen non-executive employees.
-
Shasqi Appoints Oncology Luminaries to its Inaugural Scientific Advisory Board, Alongside the Expansion of its Leadership Team
8/2/2023
Shasqi, Inc. announced the formation of its Scientific Advisory Board composed of leaders with decades of experience in oncology drug development and translational research.
-
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
7/26/2023
Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy type 1 (NT1) was published in The New England Journal of Medicine.
-
Despite the lifting of the FDA’s partial clinical hold, Gilead will discontinue magrolimab’s development in higher-risk myelodysplastic syndromes after a Phase III study met the bar for futility.
-
Allied OMS Announces Appointment of Dr. Jonathon Jundt as Chief Medical Officer
7/21/2023
Allied OMS - the country's only doctor-owned, doctor-led, and doctor-governed management services organization ("MSO") for oral and maxillofacial surgery ("OMS") practices, is pleased to announce the appointment of Jonathon Jundt, DDS, MD, FACS, as the company's Chief Medical Officer ("CMO").
-
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer
7/20/2023
Shanghai Junshi Biosciences Co., Ltd announced that the supplemental new drug application for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer, has been accepted for review by the National Medical Products Administration.
-
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
7/18/2023
PharmaTher Holdings Ltd. is pleased to announce that it has successfully completed a research study evaluating PharmaPatch™, a proprietary microneedle patch, in delivering N,N-dimethyltryptamine (“DMT”).
-
ADDF Statement on New Results from Donanemab's TRAILBLAZER-ALZ 2 Trial
7/17/2023
The Alzheimer's Drug Discovery Foundation is encouraged to see the positive data reported by Eli Lilly and Company for its anti-amyloid drug, donanemab, which was unveiled at the Alzheimer's Association International Conference in Amsterdam and published in JAMA.
-
IGC Reports Financial Results for Fiscal Year Ended March 31, 2023
7/12/2023
IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”).
-
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
7/12/2023
Shanghai Junshi Biosciences Co., Ltd announced that the supplemental new drug application for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with axitinib for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma, has been accepted by the National Medical Products Administration.